Indexed in Journament

the lancet oncology

ISSN 1474-5488· EN

Certificate of Indexing
Login or register to claim ownership or editorship of this journal.
40.1/100
Journament Score
#9,709
Journament Rank
9
Articles Indexed

About This Journal

Short Name lancet oncol
Abbreviated Name lancet oncol
ISSN 1474-5488

Indexings

scopus ncbi

Tools & Certificate of Indexing

Certificate of Indexing
Quality Badge Widget - Embed on Your Website

Display your journal's verified indexing scores on your website with our self-contained widget.

One-Line JavaScript Embed:
Advantages: Single-line script, seamless DOM integration, clickable badges linking to full journal profile.
Standard iFrame Embed Code:
Widget Preview:

Publications Per Year

Articles (9)

2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Chiappella A;Martelli M;Angelucci E;Brusamolino E;Evangelista A;Carella AM;Stelitano C;Rossi G;Balzarotti M;Merli F;Gaidano G;Pavone V;Rigacci L;Zaja F;D'Arco A;Cascavilla N;Russo E;Castellino A;Gotti M;Congiu AG;Cabras MG;Tucci A;Agostinelli C;Ciccone G;Pileri SA;Vitolo U;;
Vol. 18 , No. 8 , pp. -
545 views Abstract
2020
Radiotheranostics: a roadmap for future development.
Herrmann, Ken;Schwaiger, Markus;Lewis, Jason S;Solomon, Stephen B;McNeil, Barbara J;Baumann, Michael;Gambhir, Sanjiv S;Hricak, Hedvig;Weissleder, Ralph;
Vol. 21 , No. 3 , pp. e146-e156
502 views DOI Abstract
2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano, Mario;Schettini, Francesco;Rognoni, Carla;Milani, Manuela;Jerusalem, Guy;Bachelot, Thomas;De Laurentiis, Michelino;Thomas, Guglielmo;De Placido, Pietro;Arpino, Grazia;De Placido, Sabino;Cristofanilli, Massimo;Giordano, Antonio;Puglisi, Fabio;Pistilli, Barbara;Prat, Aleix;Del Mastro, Lucia;Venturini, Sergio;Generali, Daniele;
381 views DOI Abstract
2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos, Meletios A;Moreau, Philippe;Palumbo, Antonio;Joshua, Douglas;Pour, Ludek;Hájek, Roman;Facon, Thierry;Ludwig, Heinz;Oriol, Albert;Goldschmidt, Hartmut;Rosiñol, Laura;Straub, Jan;Suvorov, Aleksandr;Araujo, Carla;Rimashevskaya, Elena;Pika, Tomas;Gaidano, Gianluca;Weisel, Katja;Goranova-Marinova, Vesselina;Schwarer, Anthony;Minuk, Leonard;Masszi, Tamás;Karamanesht, Ievgenii;Offidani, Massimo;Hungria, Vania;Spencer, Andrew;Orlowski, Robert Z;Gillenwater, Heidi H;Mohamed, Nehal;Feng, Shibao;Chng, Wee-Joo;, ;
Vol. 17 , No. 1 , pp. 27-38
368 views DOI Abstract
2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal, Joel W;Dahlberg, Suzanne E;Wakelee, Heather A;Aisner, Seena C;Bowden, Michaela;Huang, Ying;Carbone, David P;Gerstner, Gregory J;Lerner, Rachel E;Rubin, Jerome L;Owonikoko, Taofeek K;Stella, Philip J;Steen, Preston D;Khalid, Ahmed Ali;Ramalingam, Suresh S;, ;
Vol. 17 , No. 12 , pp. 1661-1671
357 views DOI Abstract
2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong, Terri S;Dirven, Linda;Arons, David;Bates, Amanda;Chang, Susan M;Coens, Corneel;Espinasse, Claire;Gilbert, Mark R;Jenkinson, David;Kluetz, Paul;Mendoza, Tito;Rubinstein, Larry;Sul, Joohee;Weller, Michael;Wen, Patrick Y;van den Bent, Martin J;Taphoorn, Martin J B;
Vol. 21 , No. 2 , pp. e97-e103
330 views DOI Abstract
2013
Is India ready to lead the battle for fair access to medicines?
Lancet Oncology, ;
Vol. 14 , No. 6 , pp. 437
267 views DOI
2019
Erratum: Correction to Lancet Oncol 2019; 20: 408-19 (The Lancet. Oncology (2019) 20 3 (408-419) PII: S1470-2045(19)30587-X)
not, found
Vol. 20 , pp. e559
235 views DOI
2010
Pancreatic cancer: a neglected killer?
Lancet Oncology, ;
Vol. 11 , No. 12 , pp. 1107
234 views DOI
2020
Radiotheranostics: a roadmap for future development.
Herrmann, Ken;Schwaiger, Markus;Lewis, Jason S;Solomon, Stephen B;McNeil, Barbara J;Baumann, Michael;Gambhir, Sanjiv S;Hricak, Hedvig;Weissleder, Ralph;
Vol. 21 , No. 3 , pp. e146-e156
502 views DOI Abstract
2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong, Terri S;Dirven, Linda;Arons, David;Bates, Amanda;Chang, Susan M;Coens, Corneel;Espinasse, Claire;Gilbert, Mark R;Jenkinson, David;Kluetz, Paul;Mendoza, Tito;Rubinstein, Larry;Sul, Joohee;Weller, Michael;Wen, Patrick Y;van den Bent, Martin J;Taphoorn, Martin J B;
Vol. 21 , No. 2 , pp. e97-e103
330 views DOI Abstract
2019
Erratum: Correction to Lancet Oncol 2019; 20: 408-19 (The Lancet. Oncology (2019) 20 3 (408-419) PII: S1470-2045(19)30587-X)
not, found
Vol. 20 , pp. e559
235 views DOI
2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano, Mario;Schettini, Francesco;Rognoni, Carla;Milani, Manuela;Jerusalem, Guy;Bachelot, Thomas;De Laurentiis, Michelino;Thomas, Guglielmo;De Placido, Pietro;Arpino, Grazia;De Placido, Sabino;Cristofanilli, Massimo;Giordano, Antonio;Puglisi, Fabio;Pistilli, Barbara;Prat, Aleix;Del Mastro, Lucia;Venturini, Sergio;Generali, Daniele;
381 views DOI Abstract
2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Chiappella A;Martelli M;Angelucci E;Brusamolino E;Evangelista A;Carella AM;Stelitano C;Rossi G;Balzarotti M;Merli F;Gaidano G;Pavone V;Rigacci L;Zaja F;D'Arco A;Cascavilla N;Russo E;Castellino A;Gotti M;Congiu AG;Cabras MG;Tucci A;Agostinelli C;Ciccone G;Pileri SA;Vitolo U;;
Vol. 18 , No. 8 , pp. -
545 views Abstract
2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos, Meletios A;Moreau, Philippe;Palumbo, Antonio;Joshua, Douglas;Pour, Ludek;Hájek, Roman;Facon, Thierry;Ludwig, Heinz;Oriol, Albert;Goldschmidt, Hartmut;Rosiñol, Laura;Straub, Jan;Suvorov, Aleksandr;Araujo, Carla;Rimashevskaya, Elena;Pika, Tomas;Gaidano, Gianluca;Weisel, Katja;Goranova-Marinova, Vesselina;Schwarer, Anthony;Minuk, Leonard;Masszi, Tamás;Karamanesht, Ievgenii;Offidani, Massimo;Hungria, Vania;Spencer, Andrew;Orlowski, Robert Z;Gillenwater, Heidi H;Mohamed, Nehal;Feng, Shibao;Chng, Wee-Joo;, ;
Vol. 17 , No. 1 , pp. 27-38
368 views DOI Abstract
2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal, Joel W;Dahlberg, Suzanne E;Wakelee, Heather A;Aisner, Seena C;Bowden, Michaela;Huang, Ying;Carbone, David P;Gerstner, Gregory J;Lerner, Rachel E;Rubin, Jerome L;Owonikoko, Taofeek K;Stella, Philip J;Steen, Preston D;Khalid, Ahmed Ali;Ramalingam, Suresh S;, ;
Vol. 17 , No. 12 , pp. 1661-1671
357 views DOI Abstract
2013
Is India ready to lead the battle for fair access to medicines?
Lancet Oncology, ;
Vol. 14 , No. 6 , pp. 437
267 views DOI
2010
Pancreatic cancer: a neglected killer?
Lancet Oncology, ;
Vol. 11 , No. 12 , pp. 1107
234 views DOI
40
Overall
Below Average
31
15
30
40
38
50
0
0
0
0
0
Journament

Overall Quality Score

40.1/100

Tier: Below Average

The Journament Overall Quality Score is a comprehensive metric that evaluates academic journals across multiple dimensions including engagement, accessibility, diversity, innovation, and community impact.

This score helps researchers, institutions, and publishers understand the holistic quality and impact of a journal beyond traditional metrics.

Engagement Score

30.9/100

Measures user interactions, views, citations, and community involvement with this journal's content.

Higher engagement scores indicate that the journal's content is actively being read, cited, and discussed within the academic community.

Accessibility Score

15.0/100

Evaluates how easily researchers can access journal content, including open access availability, ISSN registration, and indexing.

This metric considers factors such as paywalls, open access policies, and availability across different academic databases and search engines.

Diversity Score

30.0/100

Assesses geographic and institutional diversity of authors, editorial board composition, and topic breadth.

A diverse journal publishes work from various geographic regions, institutions, and covers a broad range of topics within its field.

Innovation Score

40.0/100

Evaluates research novelty, interdisciplinary work, and emerging topics based on AI analysis of article abstracts.

This score reflects how much the journal publishes cutting-edge research, explores new methodologies, and bridges different academic disciplines.

Community Impact Score

37.5/100

Measures scholarly contribution and real-world applications of published research.

This metric evaluates how the journal's research translates into practical applications, policy changes, and benefits to society beyond academia.

Timeliness Score

50.0/100

Evaluates recent publication activity, publication frequency, and currency of research topics.

Higher scores indicate consistent publishing schedules and timely coverage of current research trends.

Ethics & Transparency Score

0.0/100

Research Integrity (10% weight)

Assesses COPE standards compliance, ethical considerations in research, transparency in methodologies, and reproducibility practices.

This metric ensures the journal maintains high ethical standards and promotes transparent, trustworthy research.

Content Quality Score

0.0/100

Academic Rigor (20% weight) + Methodology Quality (12%)

Evaluates research methodology soundness, statistical rigor, theoretical framework strength, appropriateness of research methods, data quality, and clarity & readability.

This comprehensive metric ensures published research meets the highest academic standards.

Editorial Diversity Score

0.0/100

Author Diversity + Interdisciplinary Value (8%)

Measures geographic diversity of authors, institutional variety, editorial board composition, and cross-disciplinary connections.

Diverse editorial teams bring varied perspectives and reduce bias in academic publishing.

Publication Regularity Score

0.0/100

Assesses consistency of publication schedule, frequency stability, and predictable output patterns.

Regular publication schedules indicate reliable journal operations and consistent workflow management.

Geographic Reach Score

0.0/100

Evaluates international author representation, global readership distribution, and cross-border research collaboration.

Wide geographic reach indicates global impact and international recognition of the journal's research.